Skip to content

It looks like we may have content for your preferred language. Would you like to view this page in English?

AzurRx Acquisition of Issued and Outstanding Capital Stock of ProteaBio Europe SAS

Represented AzurRx BioPharma, Inc. in connection with the entering into of a Stock Purchase and Sale Agreement with Protea Biosciences Group, Inc., Protea Biosciences, Inc. and ProteaBio Europe SAS pursuant to which AzurRx acquired 100% of the issued and outstanding capital stock of ProteaBio Europe SAS.